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Abstract: Alterations of cholesterol homeostasis represent important risk factors for 
atherosclerosis and cardiovascular disease. Different clinical-experimental approaches have 
been devised to study the metabolism of cholesterol and particularly the synthesis of bile 
acids, its main catabolic products. Most evidence in humans has derived from studies 
utilizing the administration of labeled sterols; these have several advantages over in vitro 
assay of enzyme activity and expression, requiring an invasive procedure such as a liver 
biopsy, or the determination of fecal sterols, which is cumbersome and not commonly 
available. Pioneering evidence with administration of radioactive sterol derivatives has 
allowed to characterize the alterations of cholesterol metabolism and degradation in different 
situations, including spontaneous disease conditions, aging, and drug treatment. Along with 
the classical isotope dilution methodology, other approaches were proposed, among which 
isotope release following radioactive substrate administration. More recently, stable isotope 
studies have allowed to overcome radioactivity exposure. Isotope enrichment studies during 
tracer infusion has allowed to characterize changes in the degradation of cholesterol via the 
“classical” and the “alternative” pathways of bile acid synthesis. Evidence brought by tracer 
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studies in vivo, summarized here, provides an exceptional tool for the investigation of sterol 
metabolism, and integrate the studies in vitro on human tissue. 
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Abbreviations 
CA, cholic acid; CDCA, chenodeoxycholic acid; CYP7A1, cholesterol 7α-hydroxylase;  
CYP27A1, sterol 27-hydroxylase; CTX, cerebrotendinous xanthomatosis; DCA, deoxycholic acid; 
FGF, fibroblast growth factor; FXR, farnesoid X receptor; LXR, liver X receptor; PPAR, peroxysomal 
proliferator-activated receptor; SHP, small heterodimer partner; SREBP, sterol regulatory element 
binding protein; UDCA, ursodeoxycholic acid. 
1. Introduction 
Cholesterol homeostasis in the whole organism is regulated by a complex series of interrelated 
metabolic pathways. Whenever such homeostatic balance is altered, an accumulation of cholesterol in 
one or more body compartments may take place [1], with the possible occurrence of clinically relevant 
cholesterol accumulation conditions, such as atherosclerosis or cholesterol gallstone disease. In this 
context, the liver plays a key role [2]. In the liver a delicate balance exists between input and output 
pathways [3], so that under physiological conditions no net accumulation of this sterol takes place. 
Degradation to primary bile acids represents the most relevant mechanism of irreversible 
elimination of cholesterol from the body, thus playing a key role in hepatic and systemic cholesterol 
homeostasis. Under physiological conditions, approximately 300–400 mg of cholesterol are disposed 
of in the liver daily, through this pathway [3]. 
Alterations in bile acids production can therefore have relevant consequences on the cholesterol 
content in different body compartments, as exemplified by the clinical-experimental model of the 
treatment with bile acid-binding resins, which are capable of reducing plasma cholesterol levels by 
increasing bile acid production [4]. 
Over the past two decades and with the aid of molecular biology a body of evidence has defined the 
molecular mechanisms of the regulation of cholesterol and bile acid metabolism; among others, the role of 
nuclear receptors in the control of bile acid synthesis and of the activity of cholesterol 7α-hydroxylase, the 
limiting enzyme of the “classical” biosynthetic pathway, has been highlighted [3,5–8]. Furthermore, the 
role of the so-called “alternative” pathway of bile acid synthesis, whose first step is hepatic and 
extrahepatic 27-hydroxylation of cholesterol, has been underlined [9–11]. 
Different experimental approaches have been devised to study bile acid metabolism. Together with 
the analytical assay of enzyme expression and activity in human tissue in vitro, a large amount of 
evidence has been obtained in vivo in humans with the aid of administration of labeled sterols. 
This review will summarize the main evidence coming from human studies with the use of 
radioactive or stable isotopes as metabolic tracers; such evidence has provided an extraordinary 
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contribution to our knowledge on the regulation of cholesterol degradation to bile acids, both via the 
“classical” and the “alternative” pathways of bile acid synthesis. 
2. Biochemistry of Bile Acid Synthesis 
Bile acids are final water-soluble products of cholesterol catabolism and their synthesis represents a 
relevant metabolic step in the regulation of whole body cholesterol balance. Bile acids are 24 carbon 
atom steroidal carboxylic acids derived from cholesterol. The primary bile acids in humans, cholic 
acid (CA) and chenodeoxycholic acid (CDCA), are synthesized in the liver and conjugated with 
taurine or glycine before secretion via bile into the intestine. The cholesterol conversion into CA and 
CDCA occurs prevalently in hepatocytes and involves different steps: the initiation of synthesis by 
hydroxylation of cholesterol, further modifications to the ring structures, side-chain oxidation and 
shortening by three carbons, and conjugation of the bile acid with taurine or glycine [12]. 
Two main pathways of bile acid synthesis have been described [10]. The classical “neutral” 
pathway starts with 7α-hydroxylation of cholesterol and is catalyzed by the liver-specific enzyme 
cholesterol 7α-hydroxylase (CYP7A1). This enzyme, a specific microsomal cytochrome P450 
expressed only in the liver, represents the rate-limiting step. CYP7A1 is reported to be active almost 
exclusively on cholesterol and cholestanol, its 5α-saturated analog [13], thus showing a limited 
substrate specificity. Nevertheless other authors reported that this enzyme is able to catalyze  
7α-hydroxylation also of 27-hydroxycholesterol and other oxysterols [14]. 
Bile acids returning to the liver through the enterohepatic circulation were considered as the 
effectors of a feedback control on the biosynthetic pathway [4,15,16]. Bile acid feedback inhibition of 
CYP7A1 is mediated, at least in experimental models, by the nuclear receptors farnesoid X receptor 
(FXR) and small heterodimer partner (SHP) [17]. Experimental data demonstrate that bile acids block 
the association of the coactivators peroxysomal proliferator-activated receptor (PPAR) gamma 
coactivator-1α (PGC-1α) and cAMP Response Element Binding protein-Binding Protein (CBP)  
with Hepatocyte Nuclear Factor-4α (HNF-4α) and suppress the transcription of CYP7A1 in an  
FXR-independent manner [18]. 
The 7α-hydroxycholesterol is next converted into 7α-hydroxy-4-cholesten-3-one by a microsomal 
3β-hydroxy-5-C27-steroid dehydrogenase/oxidoreductase (C27β-HSD) located in the endoplasmic 
reticulum which catalyzes the isomerization of the double bond and oxidation of the hydroxyl group in 
position 3 to an oxo group. Next, 7α-hydroxy-4-cholesten-3-one is converted to 7α,12α-dihydroxy-4-
cholesten-3-one by a sterol 12α-hydroxylase a microsomal cytochrome P-450 (CYP8B1) [19]. 
Further reduction of the 7α-hydroxy-4-cholesten-3-one and 7α,12α-dihydroxy-4-cholesten-3-one 
catalyzed by Δ4-3-oxosteroid-5β-reductase and 3α-hydroxysteroid dehydrogenase [20,21] produce the 
precursors of CDCA and CA (5β-cholestane-3α,7α-diol and 5β-cholestane-3α,7α,12α-triol, respectively). 
The subsequent side-chain oxidation of diol and triol steroids by mitochondrial sterol  
27-hydroxylase (CYP27A1) and cleavage of C24-C25 bond are the next steps in the biosynthetic 
pathway leading to primary bile acid synthesis. In humans the classical pathway is the most relevant 
one in quantitative terms, in normal condition and produces CA and CDCA acid in roughly  
equal quantities. 
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Bile acid synthesis occurs also via an “alternative” pathway for which the first step, which precedes 
the modifications to the ring nucleus, is represented by the hydroxylation of the cholesterol side chain 
at position 27 catalyzed by CYP27A1 [9,10], a mitochondrial cytochrome P-450 characterized by 
broad substrate specificity and by broad tissue and organ distribution, in particular in vascular 
endothelium, in fibroblasts and in macrophages [9]. Further steps in bile acid synthesis via this 
pathway include oxidation of 27-hydroxycholesterol to cholestenoic acid catalyzed by the same 
enzyme [22,23]. In this way sterol 27-hydroxylase promotes metabolism of cholesterol to more polar 
compounds that are more efficiently exported from cells than the parent compound [24] and 
transported through the circulation to the hepatic cells where hydroxylation at position 7α by oxysterol 
7α-hydroxylase (CYP7B1) [25] and the side chain cleavage rise particularly to CDCA.  
The role of the alternative biosynthetic pathway in quantitative terms is controversial: in human 
subjects, bile acid production via 27-hydroxylation accounts only for 10% of total bile acid synthesis [26]. 
Nevertheless the alternative pathway could represent an important means for removal of cholesterol 
deposited in endothelium and it is considered to be important in the reverse transport of cholesterol, 
from the periphery to the liver and its protective role against atherosclerosis has been proposed [27].  
In vivo conversion of cholesterol into bile acids occurs also following two quantitatively minor 
pathways involving introduction of one hydroxyl group at two different positions of side chain of 
cholesterol C24S and C25 (24- and 25-hydroxylase pathways).  
The 24-hydroxylase pathway in particular allows maintenance of cholesterol homeostasis in brain 
by conversion into 24S-hydroxycholesterol, also known as cerebrosterol. This reaction is catalyzed by 
the cholesterol 24-hydroxylase (CYP46) [28]. 24S-Hydroxycholesterol is more polar than cholesterol 
and it is able to pass the lipophilic membranes, such as the blood-brain barrier for transport through the 
circulation to the liver and further conversion to bile acids. Schemes 1 and 2 illustrate in a schematic 
way the main steps involved in the degradation of cholesterol to bile acids. 
Scheme 1. Schematic illustration of the main pathways of bile acid synthesis from cholesterol. 
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Scheme 2. Illustration of the main metabolic steps of the classical pathway of bile  
acid synthesis. 1: Cholesterol-7α-hydroxylase (CYP7A); 2: 3β-hydroxy-5-C27-steroid 
dehydrogenase (C27β-HSD); 3: Sterol 12α-hydroxylase (CYP8B1); 4: Δ4-3-oxosteroid-5β-
reductase; 5: 3α-hydroxysteroid dehydrogenase. 
 
3. Alternative Approaches for the Quantification of Bile Acid Synthesis 
Extensive review of the different procedures and techniques adopted in the past and at the present 
time to measure bile acid synthesis is way beyond the aims of the present paper. Only a brief mention 
will be made to alternative techniques such as in vitro assays, fecal sterol analysis, and determination 
of plasma concentrations of non-cholesterol sterols. 
The determination of bile acid synthesis and the study of the alterations induced by disease 
conditions and by treatment have long relied upon the assay in vitro of the expression and activity of 
the limiting enzyme, CYP7A1, and, more recently, of CYP27A1.  
Since the 1960s pioneering evidence has been obtained with the assay of CYP7A1 activity after 
isolation of liver microsomes [29,30]. Such assays have utilized radioactive isotopes and, in more 
recent years, stable tracers for the determination of CYP7A1 activity. Using these techniques, results 
of paramount importance have been obtained in the field of the physiology and pathophysiology of the 
regulation of bile acid synthesis, including the relevance of the physical-chemical properties of bile 
acids, often replicating in humans the results obtained in animal models [3,15,19]. Evidence on the 
role of 27-hydroxylase has emerged as well over the past decades [9,10], even if direct studies in 
human subjects have been extremely scarce in this regard, despite the fact that CYP27A1 is expressed 
also in macrophages, which are easily obtainable from circulating blood, after isolation of monocytes 
and in vitro monocyte/macrophage differentiation [31]. 
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More recently, translational research has been extended to the assay of tissue gene expression 
(mRNA) and protein content, for both CYP7A1 and CYP27A1 [3,7,8]. 
An obvious limit of all in vitro procedures is the need to obtain tissue (usually liver) specimens; these 
can usually be obtained during surgical procedures, or by means of non-surgical biopsy. The relative 
invasiveness and inherent ethical problems clearly represent a major drawback with this kind of approach. 
Analysis of fecal sterols has extensively been utilized, in the attempt to overcome the need of ex vivo 
tissue samples. The measurement of fecal acidic sterols can provide an indirect measurement of whole 
body synthetic rates [32–34]. This has been tested and validated in several experimental situations [35,36]. 
This approach too has yielded important results in the knowledge of the regulation of bile acid 
synthesis. Nonetheless, it requires accurate fecal collection and the techniques for the analytical 
determinations are usually rather complex, making this approach not suitable for wide scale utilization. 
Finally, the determination of plasma or serum levels of hydroxylated sterols which represent 
metabolic intermediates in the biosynthetic pathway has been extensively utilized as an indirect 
measure of bile acid synthesis or of some of its rate-limiting steps.  
The assay of circulating levels of 7α-hydroxycholesterol, the end-product of the reaction catalyzed 
by CYP7A1, has been proposed for long time as an indirect measurement of bile acid synthesis  
and of CYP7A1 activity, particularly in stimulated conditions [37,38]. Analysis of the more stable 
metabolite 7α-hydroxy-4-cholesten-3-one (C4) has also been used as a surrogate marker of bile acid 
synthesis rates [39–42]. 
Similarly, the determination of serum levels of 27-hydroxycholesterol has been used as an index of 
hepatic and extrahepatic CYP27 activity, and therefore of the initial steps in the alternate pathway of 
bile acid synthesis [31,43–45].  
The simplicity and convenience of similar approaches, requiring a single blood sample, makes them 
ideal for large-scale investigation, if not for routine analysis. We need to keep in mind, though, that this 
kind of determination can only provide semi-quantitative estimates of bile acid synthesis and therefore 
cannot be utilized in the evaluation of homeostatic changes of cholesterol and bile acid metabolism. 
4. Use of Radioactive Tracers for the Measurement of Bile Acid Synthesis 
The gold standard technique for the determination of total bile acid synthesis in humans in vivo has 
been represented, over the past half-century, by the isotope dilution method, in origin described by 
Lindstedt in the late 50s [46]. Such a technique is based on the principle that bile acid turnover 
undergoes first order kinetics and therefore, after labeled bile acid administration, their specific 
radioactivity decreases monoexponentially with time. According to this approach, oral administration of 
radioactive derivatives of bile acids, usually cholic acid (CA) and chenodeoxycholic acid (CDCA) 
labeled with either [14C] or [3H], is followed by serial duodenal bile sampling over the following  
days [46,47]. 
Liquid scintillation analysis of the radioactivity in bile samples, usually following bile acid 
extraction and separation, allows determination of turnover rate, pool size and synthetic rate of primary 
bile acids. 
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This technique is relatively simple and non-expensive; it has the inconvenience of the need for 
repeated bile sampling, which is usually obtained by duodenal intubation, a procedure not well 
tolerated by most patients. 
A simplification of such techniques has been later proposed [48] consisting in administration in 
different time points of CA and CDCA labeled with different tracers followed by a single bile 
collection, thus minimizing the inconvenience of duodenal intubation. Multi-compartmental model 
analysis was also adopted to define the kinetic parameters of administered bile acids [49]. 
Combined administration of radiolabeled tracers can allow selective estimation of the relative 
contributions of the “classical” and “alternate” pathways of bile acid synthesis, as more recently 
proposed by Duane and Javitt [50]. Administration of [14C]-labeled CA and CDCA together with  
[7β-3H]7α(OH)cholesterol or [22,23-3H]27(OH)cholesterol was used, allowing to calculate the 
production rates of primary bile acids by classical isotope dilution technique, and to estimate the 
relative contribution of the two precursors from the [3H/14C] ratio in CA and CDCA. 
Alternative procedures to isotope dilution have also been proposed with the approach of isotope 
release. The technique described by Rosenfeld et al. [51,52] is based upon i.v. administration of 
[24,25-3H]cholesterol. After side chain cleavage of the cholesterol molecule, [3H] release is 
proportional to, and can provide an estimate of, bile acid synthesis rate. This can be calculated as the 
ratio between body water tritium enrichment, assayed after distillation of red blood cells, and the 
specific activity of plasma cholesterol in plasma. 
A similar approach has been described by Duane and coworkers with the measurement of [14C]CO2 
release after i.v. administration of [26-14C]cholesterol; here, like in the previous approach, the 
technique can estimate bile acid synthesis by determination of side chain cleavage. According to this 
methodology, the output of [14C]CO2 is collected from the breath at time intervals after tracer 
administration, with the aid of an air-trapping device [53]. The rate of bile acid synthesis can be 
calculated as the ratio between the output of [14C]CO2 and the specific radioactivity of plasma 
cholesterol, measured in the same time frame. This procedure was also described to detect short-term 
changes of bile acid synthesis rates, as occurring after bolus drug administration [54]. A disadvantage 
of this approach is the requirement for a dedicated breath-collecting apparatus. 
Another isotope release approach has been developed by our group over the past three decades: this 
approach is based upon the principle that cholesterol 7α-hydroxylation, the first and rate-limiting step 
of the biosynthetic pathway, is a highly stereospecific reaction whereby a tritium atom at the 7α 
position is replaced by a hydroxyl group. After i.v. administration of a bolus of [7α-3H]cholesterol the 
amount of tritium exchanged will reflect the extent of the 7α-hydroxylation reaction and therefore the 
rate of bile acid synthesis. The latter can be directly calculated as the ratio between tritium enrichment 
in the body water pool (determined after distillation of biologic fluids, either blood or urine) and the 
specific radioactivity of serum cholesterol, analyzed in the same time period [55]. Because tritium 
release from the 7α position is independent of the specific enzymatic reaction involved, this assay can 
detect the amount of cholesterol degraded both via the classical and the alternate pathways. 
This technique has proven extremely useful in detecting changes in bile acid synthesis in different 
clinical-experimental conditions (see later) and has been shown to correlate well with the assay of 
serum levels of 7α-hydroxy-4-cholesten-3-one, as an indirect measure of bile acid synthesis and of 
CYP7A1 activity [42]. 
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A relative drawback with this technique is the need to obtain sufficient amounts of [7α-3H]cholesterol 
with a high degree of specific localization of the radiolabel at the 7α-position. 
5. Use of Stable Isotopes for the Measurement of Bile Acid Synthesis 
5.1. Bile Acid Kinetics Studies 
All of the aforementioned techniques share the inconvenience of the systemic exposure of patients 
to ionizing radiations. Even if this can be theoretically quantified, and the amount of radioactivity 
absorbed was usually estimated not to exceed that of a routine radiological procedure [55], the risk of 
tissue damage from radioactivity has to be taken carefully into account, together with the inherent 
ethical concerns. The use of stable isotopes should theoretically overcome these safety concerns and 
indeed over the last decades a number of techniques have been developed with these compounds. 
Since the 1970s, different research groups have described isotope dilution approaches, closely 
resembling that described earlier by Lindstedt, utilizing stable isotopes of CA and CDCA: respectively 
[24-13C]CA and [24-13C]CDCA [56–58]. Following oral administration of these isotopes, serum and 
bile samples are collected over the following days and analyzed for isotope enrichment by gas 
chromatography-mass spectrometry (GC-MS) [58–60]. Fractional turnover rates, pool size and 
synthesis rates of bile acids can subsequently be calculated as for the radioactive isotope technique. 
Notably, the measurements from serum samples substantially equaled those from bile. In a similar 
fashion, the kinetics of secondary bile acids such as deoxycholic acid (DCA) (pool size, input rate) 
could be determined [61]. 
In addition, the same research groups described dual isotope procedures for measuring the steady 
state kinetics of primary and secondary bile acids, using [2H] and [13C]-labeled bile acids, and serum 
sampling [58,62,63].  
A brief mention needs to be made to a novel technique, which has been adopted over the last 
decades to study cholesterol and bile acid metabolism. This technique relies on mass isotopomer 
distribution analysis (MIDA) of tracer isotopes as an indirect estimate of isotope enrichment in the 
precursor pool, and allows the calculation of sterol precursor rates from the direct determination of 
isotope enrichment in the product. This approach can mainly address the contribution of newly 
synthesized cholesterol to bile acid synthesis [64]. 
5.2. Studies on the Relative Contributions of the Classical and Alternate Pathways 
As reported above, two bile acid synthesis pathways have been described: the classical, occurring in 
the liver and the alternative one, starting in extra-hepatic tissues [23] and many efforts have been  
done to explore their relative contribution. Plasma concentrations of 27-hydroxycholesterol and  
7α-hydroxycholesterol may be useful to obtain indirect data on this issue, but more information may 
be obtained by kinetics studies since quantification of metabolic events can be achieved using tracer 
procedures with stable isotopes [65]. The endogenous rate of production of a metabolite can be 
calculated from its isotopic enrichment knowing the rate of infusion and plasma concentration of the 
tested compound under steady state conditions. Therefore, the measurement of the production rate of 
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27-hydroxycholesterol and 7α-hydroxycholesterol may be used to separately evaluate the two 
pathways of bile acid synthesis. 
Duane and Javitt used for the first time plasma enrichment with isotopes of 27-hydroxycholesterol 
to explore the alternative pathway by measuring the production rate of such oxysterol. A constant 
infusion of [2H]27-hydroxycholestrol was used to evaluate 27-hydroxycholesterol production rate in 
normal subjects [26]. Cholesterol 27-hydroxylation pathway averaged approximately 10% of total bile 
acid synthesis, as evaluated by measuring fecal acidic sterol output. This estimate was based on the 
rate of 27-hydroxycholesterol production obtained by isotope dilution after 6–10 h of infusion while 
total bile acid synthesis had been previously calculated from the 72 h fecal acidic sterol output [26]. A 
nearly complete equilibrium of the infused 27-hydroxycholesterol isotope between serum and liver 
was shown and the steady state was rapidly achieved. The main limitation of this evaluation refers to 
the fact that the production rate of 27-hydroxycholesterol evaluated during few hours under fasting 
conditions was compared with a total bile acid synthesis estimated over a three-day period. Therefore 
the effects of the alimentation status and of circadian rhythms may render not comparable kinetic data 
obtained in such different periods of time. In addition the inter-day variability of cholesterol 
catabolism, mainly through bile acid synthesis, which may occur in normal human subjects as we have 
observed [66], suggests that the estimation of 10% for the relative contribution of the alternative 
pathway of bile acid synthesis may be not accurate. 
To overcome these limitations a minimally invasive technique, using 2 h infusions of isotopomers 
of 27-hydroxycholesterol and 7α-hydroxycholesterol was evaluated to simultaneously explore the two 
major pathways of bile acid synthesis [66]. The steady state was found to be rapidly achieved, 
however, also this approach has several shortcomings, mainly due to lack of validation of the 
estimation of the production rate of 7α-hydroxycholesterol. In fact, for 27-hydroxycholesterol, the rate 
of plasma appearance was previously shown to correspond to its production rate [26] but this may not 
be the case for 7α-hydroxycholesterol since 7α-hydroxylation is a liver-specific reaction, and the 
kinetics of the liver-plasma exchange of 7α-hydroxycholesterol are still unknown. In particular, as 
indicated by experimental observations [66], the isotope ratio for 7α-hydroxycholesterol, reflecting 
dilution with newly synthesized sterol, in the liver may be lower than in plasma and such systematic 
overestimation of the isotope ratio may lead to systematic underestimation of the production rate. To 
obtain an accurate measure of the production rate of 7α-hydroxycholesterol, only invasive techniques 
to sample liver tissue may be useful. However, even if the rate of plasma appearance of  
7α-hydroxycholesterol measured with the isotope dilution techniques may not accurately measure the 
absolute value of its synthesis, it may be adequate to study modifications in the classical pathway 
under different conditions. 
In conclusion, though many efforts have been made to explore the relative contribution of the 
classical and alternative pathways of bile acid synthesis using stable isotope dilution techniques, only 
indirect data are still available. Interestingly, in adult subjects, only for 27-hydroxycholesterol plasma 
concentration was shown to reflect the production rate [31].  
The above mentioned procedures can thus provide useful and reliable information on bile acid 
kinetic parameters, on one side, and on the production rates of 7α-hydroxycholesterol and  
27-hydroxycholesterol on the other, the latter being a direct reflection of the efficiency of the classical 
and alternate biosynthetic pathways. These procedures require analysis by GC-MS, rather 
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sophisticated equipment available only in dedicated laboratory facilities. On the other hand, the 
absence of safety concerns with the use of stable isotopes makes this approach ideal for human studies, 
and is therefore believed to completely replace the older radiolabel-based techniques. 
6. Regulation of Bile Acid Synthesis in Different Situations 
Regarding the classical pathway, the rate of transcription, rather than the rate of translation,  
appears to be the main determinant of the enzymatic activity of CYP7A1 under most physiological 
circumstances [67]. Reduction in CYP7A1 activity in humans is known to occur with oral 
administration of CDCA [68], whereas the interruption of the enterohepatic circulation increases its 
activity thus implying that the bile acid pool size is auto-regulated by the binding of bile acids to the 
FXR receptor [69]. In case of interruption of the enterohepatic circulation of bile acids, bile acid 
synthesis is up-regulated and also the receptor for LDL may be up-regulated [44]. Evidence has been 
provided in different species including humans, that the intestinal flux of bile acids regulates serum 
levels of intestinal fibroblast growth factors (FGF15-FGF19) that in turn modulate bile acid production 
in the liver by regulating CYP7A1 activity [70,71]. 
With regards to the alternative pathway of bile acid synthesis, the regulation of CYP27A1 is relevant 
mainly for cholesterol reverse transport and protective mechanisms against atherosclerosis. Both  
27-hydroxycholesterol and 3β-hydroxy-5-cholestenoic acid, have regulatory functions on cholesterol 
metabolism, such as the down-regulation of cholesterol synthesis via the sterol regulatory element 
binding protein (SREBP)/SREBP cleavage-activating protein (SCAP) regulatory pathway [72] and  
up-regulation of ABC transporter expression, via the liver X receptor (LXR) [73,74]. In cultured cells 
CYP27A1 was found to be transcriptionally up-regulated by some nuclear receptors, such as retinoid 
X receptor (RXR) and PPAR gamma [75,76], thus suggesting a possible protective role of these 
receptors against atherosclerosis. 
No kinetics data are available in pediatric settings, but indirect data based on plasma concentrations 
of oxysterols suggest that the physiologic cholestasis in newborn derives from the immaturity of both 
pathways of bile acid synthesis [77]. Hepatic cholesterol 7α-hydroxylase activity is absent during fetal 
life in humans and is up-regulated after birth [44,78]. The classical pathway of bile acid synthesis was 
shown to increase with age, indicating a complete maturity of the 7α-hydroxylase pathway occurring 
after the age of 4 years [77]. Also the extra-hepatic pathway of bile acid synthesis is immature in 
newborn and an efficient up-regulation was observed from the age of 4 years, which was comparable 
to that found in adult life [77]. 
With the aid of techniques adopting both radiolabeled and stable isotopes, an enormous body of 
evidence has been obtained in recent years on the pathophysiology of bile acid synthesis and its 
regulation in humans in vivo, both in spontaneous physiological and pathological conditions and 
during treatment. 
In some instances, the determination of the relative contribution of the two pathways of bile acid 
synthesis was also possible. 
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6.1. Aging 
Aging associates with important metabolic alterations. Evidence with varying experimental 
approaches in vivo utilizing radioactive tracers have shown a progressive reduction of bile acid 
synthesis with advancing age [79,80]. This is consistent with recent findings [81] confirming a 
negative correlation among age and hepatic expression of CYP7A1, and serum levels of 7α-hydroxy-
4-cholesten-3-one as an indicator of bile acid synthesis and CYP7A1 activity [39,40]. Alterations of 
hepatic nuclear receptor expression were also described, and correlated with the observed reduction of 
insulin-like growth factor I (IGF-I), the active metabolite of GH [81]. Altogether, these results appear 
to suggest a causal relationship between IGF-I levels and bile acid synthesis, which may involve 
nuclear receptors as co-regulators. 
Such changes in bile acid synthesis are likely to account for some metabolic alterations observed 
with aging, such as increased biliary cholesterol secretion and saturation [79] as well as the increase of 
serum cholesterol observed in some epidemiological studies [82]. 
6.2. Liver Disease and Cholestasis 
Cholesterol metabolism is affected in patients with liver disease for several reasons: (1) cholesterol 
synthesis occurs within the liver; (2) the large majority of the enzymes involved in bile acid synthesis, 
which represent the main step for cholesterol elimination, are located within the liver and (3) bile 
secretion is fundamental for cholesterol elimination. Therefore liver disease is characterized by 
reduction of cholesterol synthesis, especially in the presence of impaired liver function and, therefore, 
low plasma concentrations of cholesterol occur in more severe disease [83]. On the other hand, chronic 
cholestasis is commonly associated with hypercholesterolemia and marked alterations of the 
enterohepatic circulation of bile acids characterized by decreased biliary secretion with elevated serum 
levels of bile acids [83,84].  
In the presence of impaired liver function, bile acid synthesis was found to be reduced [31,55,85] 
and the reduction was found to be related to the severity of liver disease. Such suppression of bile acid 
synthesis might reflect a reduction in functioning liver mass, although radioactive isotope studies seem 
to suggest that CA synthesis is more severely affected than CDCA synthesis [86] (see later). 
Finally, data have been obtained with stable isotope administration in a cohort of patients receiving 
orthotopic liver transplantation, showing no differences in bile acid kinetic parameters and synthetic 
rates when compared with controls [87]. 
The role of cholestasis remains to be established, especially in view of the surprising observation that 
in experimental cholestasis in the rat the activity of 7α-hydroxylase is even increased [88]. However, in 
humans with obstructive cholestasis evidence is controversial: in patients, bile acid synthesis was 
reported to be reduced [89,90] even in the absence of changes in CYP7A1 expression [90], whereas 
another paper reported decreased expression of CYP7A1 associated with changes in FGF-19 
expression, normally expressed at the intestine level, being FGF-19 mRNA detected in cholestatic but 
not in normal liver [91]. 
Data in animal models have suggested a posttranscriptional inhibition of CYP7A1 activity by 
oxysterols accumulating in the cholestatic liver [92]. No evidence for increased levels of such sterols 
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has been found in human livers from cholestatic patients [90], however such possibility cannot be 
completely ruled out.  
Fewer pieces of evidence are available in chronic intrahepatic cholestasis; stable isotope studies 
showed either no change in kinetic parameters [93] or, in subjects with sclerosing cholangitis, a 
reduction in the recirculating pool of primary bile acids [94].  
Kinetic data obtained in patients with liver disease indicate that the classical pathway of  
bile acid synthesis is affected since a significant reduction of the rate of plasma appearance of  
7α-hydroxycholesterol was found in patients with liver disease (chronic hepatitis C or primary biliary 
cirrhosis) and the defect of the classical pathway was related to the severity of the disease, being the 
reduction of 7α-hydroxycholesterol plasma appearance more marked in patients with more severe 
disease [31]. Further studies are needed to separately evaluate the effects of impaired liver function 
and of cholestasis on the classical pathway of bile acid synthesis. 
Finally, kinetic data recently obtained indicate that in patients with liver disease the alternative 
pathway of bile acid synthesis is completely preserved. In patients with liver disease (chronic hepatitis 
C or primary biliary cirrhosis), the production rate of 27-hydroxycholesterol was found to be similar to 
that found in a control group of subjects with normal liver function. Therefore this mechanism which 
is involved in the reverse transport of cholesterol is completely preserved in patients with liver disease. 
This may be the reason why neither increase in cardiovascular risk nor accelerated atherosclerosis 
were found in these hypercholesterolemic patients with liver disease [83,95]. 
6.3. Nutrition and Obesity 
The alterations of cholesterol metabolism associated with obesity have been extensively studied in 
the past, in the attempt to define a causal relationship and possible clues in the pathogenesis of 
gallstone disease. Radioisotope studies have shown that a linear correlation may exist between body 
weight and the production rate of primary bile acids [96]. Nonetheless, in obese subjects bile tends to 
be supersaturated in cholesterol [97,98] and this was ascribed mainly to an increase in cholesterol 
synthesis in these subjects. The evidence, although scarce, on hepatic CYP7A1 activity in vitro [99] 
also supports the view of an increased bile acid formation in obesity. Increased mobilization of 
cholesterol from peripheral tissues might also play a role in bile supersaturation. 
When, more recently, the production rates of 7α-hydroxycholesterol were assayed by means of a 
stable isotope infusion, no relevant changes on the classical pathway of bile acid synthesis have been 
reported in obese patients, when compared to normal weight subjects [11].  
Preliminary data with stable isotopes also suggest that the production rate of 27-hydroxycholesterol 
is higher in obese patients compared to healthy subjects [11], thus suggesting that the alternative 
pathway plays a protective role against atherosclerosis in obese patients, as recently suggested also for 
hypercholesterolemic patients (see later). 
Interestingly, in obese patients, CA synthesis was reduced during a low-calorie diet [100]. This 
phenomenon has to be taken into account in view of the possible increase in the risk for cholesterol 
gallstone development, particularly with drastic dieting.  
The effects of modifications of dietary cholesterol intake on bile acid synthesis have been studied 
with the aid of radiolabeled tracers. Some evidence in humans would support an increase in conditions of 
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increased cholesterol consumption [101,102], whereas other reports failed to describe an augmentation in 
total bile acid production, measured by classical isotope dilution technique, but showed a relative 
increase in CDCA synthesis [103]. Interestingly in gallstone patients bile acid synthesis, measured by 
stable isotope administration, tended to decrease rather than to increase with a cholesterol-rich diet [104]. 
No direct evidence is available on the molecular mechanisms underlying the possible changes induced 
by cholesterol feeding; a role for nuclear receptors (LXR α in particular) would seem plausible, even if 
functional LXR-binding elements are not present in human CYP7A1 promoter [3]. 
In human subjects fasting was shown to associate with a reduction of CA synthesis, measured by 
radioisotope dilution technique, in the absence of changes in total bile acid and CA pool size [105]. 
Animal models of fat-free diet feeding [106] and of total parenteral nutrition [107] showed reduced 
bile acid synthesis rates, measured by different techniques. Similarly, patients receiving artificial 
nutrition showed a significant reduction in cholesterol 7α-hydroxylation rates measured by the isotope 
release approach, compared with control subjects (Bertolotti et al, personal observations). In such 
conditions the reduction in bile acid synthesis seems to be related to a condition of reduced intestinal 
need for bile acids for absorptive purposes; gastrointestinal hormones and FGF-19 levels might play a 
relevant role in this regulation.  
The clinical implications of such findings are obvious, considering the high incidence of 
hepatobiliary complications related to alterations in bile acid metabolism, such as cholelithiasis and 
cholestasis, during parenteral nutrition.  
Recently, it has been shown by means of stable isotope procedures that total bile acid synthesis 
decreases both during a low-fat and a high-fat diet, although probably with different mechanisms [108]. 
Finally, radioisotope kinetics studies in vegetarians showed a slight reduction in CA output, 
associated with a slight increase in DCA input rate [109]. 
6.4. Metabolic and Endocrine Disorders 
The alterations associated with diabetes have been studied in the past. Older studies [110,111] have 
shown rather inconsistent results, mainly because of heterogeneous patient populations. More recently 
Brufau et al., using a stable isotope approach, have demonstrated an increased synthesis rate of CA 
(but not of CDCA) and an increased input of DCA in patients with type 2 diabetes [112]. Furthermore, 
the inverse correlation between synthesis rates and serum FGF-19 levels tended to disappear in 
diabetic patients. The implications of these findings still have to be defined. 
The changes of bile acid synthesis associated with primary hyperlipidemias have also been studied 
extensively. In familial hypercholesterolemia, a disease characterized by reduced expression of  
LDL-receptors in the liver, bile acid synthesis does not seem to be affected [113,114] suggesting that 
receptor-mediated internalization of cholesterol is not essential for conversion to bile acid. The data is 
consistent with older evidence in patients with phenotype II hyperlipidemia according to Frederickson, 
where no significant differences in total bile acid synthesis were detected, compared with control, even 
if a reduced synthesis rate of CA was documented [96]. 
In forms of hyperlipidemia when hypertriglyceridemia is also present, such as Frederickson type IV 
hyperlipidemia [96] or, in more recent evidence, familial combined hyperlipidemia [114] and familial 
hypertriglyceridemia [115], bile acid synthesis is increased. In such conditions increased hepatic 
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production of lipoprotein probably takes place, supporting a coordinate regulation between synthesis 
of bile acids and lipogenesis; this relationship is still far from being defined in its molecular 
mechanisms, details but is likely to involve hepatic nuclear receptors (SREBPs in particular).  
When considering the alternate pathway of bile acid synthesis, in hypercholesterolemic patients  
27-hydroxycholesterol plasma concentrations were found consistently higher compared with 
normocholesterolemic patients [31]. Data on the endogenous production rate of 27-hydroxycholesterol, 
measured by stable isotope infusion, have shown either similar values in normo- and 
hypercholesterolemic patients [11], or an increase in hydroxylation rates in the latter [116]. At any 
rate, it can be suggested that higher plasma concentrations are related to increased availability of the 
substrate rather than to increased enzymatic activity. Whether this might be considered a protective 
mechanism versus atherogenesis is still debated [27,117]. 
Alterations of thyroid function profoundly affect cholesterol metabolism, and in particular plasma 
cholesterol levels, which are typically raised in hypothyroidism and reduced in hyperthyroidism. 
Therefore, the presence of a correlation between such alterations and modifications of bile acid 
synthesis has been investigated. Indeed, a study with radioactive tracers in hypothyroid patients did not 
show any differences in bile acid synthesis rates in comparison with normal controls [118], and a more 
recent study with stable isotopes showed a rather unexpected slight reduction in synthesis rates in 
hyperthyroid subjects [119]. These pieces of evidence altogether do not support the view that 
modifications in cholesterol degradation to bile acids underlie the observed changes in plasma 
cholesterol. Additional evidence with radioactive tracers however, comparing the two conditions, 
showed significantly higher rates of bile acid synthesis in hyperthyroidism compared to 
hypothyroidism [120], consistently with the known metabolic effects of thyroid hormone.  
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease 
characterized by non functioning CYP27A1, resulting in a defective alternative pathway, and  
abnormal deposition of cholestanol and cholesterol in many tissues, including the central nervous 
system [121,122]. The disease is associated with enhanced risk of premature atherosclerosis and 
derangement of bile acid metabolism during early life. In these patients data indicating increased 
production rate of 7α-hydroxycholesterol have been reported thus suggesting an up-regulation of the 
classical pathway of bile acid synthesis [123,124]. 
Recently, a new metabolic disorder caused by a homozygous frameshift mutation in the human 
CYP7A1 gene, that causes the loss of the active site and enzyme function, has been identified in three 
subjects presenting hyperlipidemia, statin-resistant hypercholesterolemia, premature gallstone disease. 
In these patients, only data on 27-hydroxycholesterol plasma concentrations are available, suggesting 
that the alternative pathway of bile acid synthesis is up-regulated [125]. Altogether, the changes 
observed in the two latter genetic metabolic diseases suggest a mutual regulation of the two pathways 
of bile acid synthesis. 
Alterations in bile acid synthesis might theoretically occur in other disorders of cholesterol 
metabolism. For instance, Niemann-Pick type C (NPC) disease is a rare and fatal inherited condition, 
caused by mutations in the NPC1 or (more rarely) in the NPC2 genes. Both gene products are involved 
in intracellular cholesterol trafficking and ultimately in cholesterol export, so that functional mutations 
result in abnormal accumulation of cholesterol in most cells of the organism, including vital tissues 
such as brain, lung and liver [126]. In this condition, alterations of cholesterol degradation to bile acids 
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might be expected; in particular, an increase in the degradation via the different pathways would seem 
plausible. Indeed, in animal models of NPC disease this does not seem to take place, as shown by  
Xie et al. [127], probably, as the Authors suggest, due to defective access of excess free cholesterol to LXR 
or to the pools acting as a substrate for CYP7A1 or CYP27A1. The issue is challenging and certainly 
deserves additional evidence, particularly in humans where no direct data are presently available. 
6.5. Gallstone Disease 
Cholelithiasis is a prevalent disease in the Western world, with a high burden of morbility and 
health costs. In the past, different attempts have been made to define the presence of single alterations 
of hepatic cholesterol metabolism which could predispose to increased cholesterol secretion and 
gallstone formation. In the last few years, alterations of hepatic expression of nuclear receptors has 
also been investigated in this context [128,129]. 
On one hand, some pieces of evidence in humans appeared to suggest that a reduction in cholesterol 
degradation to bile acids could be a predisposing factor for increased biliary cholesterol secretion. This 
was described in in vivo kinetic studies with radioisotope administration [130] and confirmed by  
in vitro assay of reduced CYP7A1 activity [131]. 
This might apply also to peculiar conditions, as fibrate treatment, where reduced bile acid  
synthesis was shown to associate with increased cholesterol secretion, in radioisotope kinetic  
studies [114,132,133] (see later). On the other hand, evidence of increased circulating levels of  
7α-hydroxy-4-cholesten-3-one seems to support the existence of a condition of bile acid malabsorption 
as a factor associated with gallstone prevalence [134]. 
Additional evidence with radioisotope studies indeed showed no or little changes in bile acid synthesis 
in gallstone subjects, even if the pool size of primary bile acids tended to be decreased [135–137];  
the finding was interpreted as an impairment in the storage capacity of the gallbladder. More recent 
evidence with stable isotope administration also failed to detect changes in bile acid production rate in 
gallstone patients, with an increase in DCA formation [138]. 
Cholecystectomy on the other hand was not found to induce significant alterations in CA 
production rates in older evidence using radioisotope administration [139]; more recent studies with 
stable isotopes though showed a slight but significant decrease in CA synthesis, and an increase in  
the fractional conversion of CA to DCA, with no changes in the total formation rate of DCA in 
consideration of the reduced synthesis of CA [140]. 
The issue of the possible alterations of cholesterol degradation in gallstone disease is therefore still 
unsettled [141]. When liver tissue was systematically assayed for specific enzymatic alterations, no 
definite evidence was shown [142]. Cholelithiasis most likely stands as a multi-factorial conditions, 
involving a number of genetic, pathophysiological and environmental factors ultimately leading to 
increased biliary cholesterol saturation which, in the presence of favouring conditions (alterations in 
gallbladder motility, infection and so on) can trigger nucleation and stone production. In this scenario, 
bile acid malabsorption might reasonably be considered as an additional risk factor. 
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6.6. Bile Acid Feeding 
Bile acids are physiological regulators of biliary lipid metabolism; the effects of the modulation of 
the bile acid pool on biliary secretion are well known [143], and the effects on different pathways of 
cholesterol homeostasis have been described as well [144]. 
The changes induced by treatment with bile acids on bile acid production have been extensively 
studied. Bile acid administration was shown to reduce bile acid synthesis and CYP7A1 activity. This 
finding, in addition with the evidence on cholestyramine (see later), strongly supports the view of an 
inhibitory feedback regulation exerted by bile acids recirculating to the liver. Such inhibitory effect is 
particularly evident with hydrophobic bile acids, such as CDCA and DCA. On the other hand, 
treatment with hydrophilic bile acids such as ursodeoxycholic acid (UDCA) generally failed to  
show any inhibitory effect. This was clearly documented with the assay of CYP7A1 activity in human  
liver [68] and in studies in vivo utilizing different experimental procedures: the classical  
isotope dilution technique using radioactive bile acids [145–147], isotope release of [3H]H2O from 
[7α-3H]cholesterol [4] and of [14C]CO2 after administration of [26-14C]cholesterol [148], and with the 
use of stable isotope administration [149]. 
Similar data were obtained in patients with chronic cholestatic conditions or with obesity, where 
treatment with UDCA generally failed to show a significant inhibitory effect on bile acid synthesis 
rates [93,94,100,150]. 
These data underscore the relevance of the hydrophobic-hydrophilic properties of the recirculating 
bile acid pool in the control of bile acid synthesis, in agreement with a wide body of evidence in 
animal models [15,151]. The molecular mechanisms of regulation of bile acid synthesis, and the 
transcriptional control of the limiting enzyme of the classical biosynthetic pathway, CYP7A1, have 
been elucidated in recent years and the role of nuclear receptors, including the bile acid receptor FXR, 
at least in experimental models, has been underlined [5,7,8]. However, the role of nuclear receptors in 
the physiological regulation of bile acid synthesis and of CYP7A1 expression in humans is still largely 
unknown [3,81,152].  
It has to be further recalled that the changes induced on CYP7A1 expression and activity in vitro do 
not always reflect bile acid synthesis. For instance, treatment with DCA was shown to reduce bile  
acid synthesis measured in vivo with radioactive tracers, both by isotope dilution [146] and by  
isotope release [4], and also to reduce circulating levels of 7α-hydroxy-4-cholesten-3-one, a marker  
of bile acid synthesis [153]; however, no changes in steady-state mRNA levels of CYP7A1 were 
observed [154]. These findings might be consistent with the presence of multiple levels of regulation 
of bile acid synthesis, including transcriptional and non-transcriptional control of CYP7A1 activity. 
Additional evidence is required in this field. 
6.7. Drug Treatment 
6.7.1. Agents Affecting Lipid Metabolism 
Lipid-lowering drugs represent a unique model to investigate the effects of modifications of 
cholesterol and triglyceride homeostasis on bile acid metabolism. 
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Bile acid-binding resins like cholestyramine and colesevalam are a powerful tool to obtain  
parallel changes in bile acid synthesis and plasma cholesterol levels. Increased fecal bile acid loss 
reduces the inhibitory feedback mechanism on CYP7A1 activity and on bile acid synthesis in  
the liver [4,49,155,156]. The increased degradation of cholesterol triggers increased HMG-CoA 
activity, enhanced expression of hepatic LDL receptors and a parallel reduction of plasma  
LDL-cholesterol levels [4]. Involvement of the SREBP regulatory pathway in this process is likely. A 
role of FGF-19 in the up-regulation of bile acid synthesis was also described [71]. 
The findings obtained with cholestyramine were more recently replicated with colesevelam in 
diabetic patients with the use of stable isotopes [112]. Colesevelam treatment was also shown to 
increase the contribution of de novo synthesized cholesterol to primary bile acids [157]. 
Fibric acid derivatives, or fibrates, have long been used in the treatment of hypertriglyceridemia. 
The hypolipidemic effects of fibrates are largely mediated by the nuclear receptor PPARα, with 
transcriptional activation of a number of genes involved in lipid and apolipoprotein metabolism. In the 
past, a body of evidence has described an association between fibrate treatment and increased 
incidence of cholesterol gallstone disease due to increased biliary cholesterol saturation. This was 
consistently related to a reduction of bile acid synthesis, as shown with radioisotope release in vivo, 
and of CYP7A1 activity [114,132,133], with a subsequent increase of intracellular availability of free 
cholesterol recruitable for biliary secretion. 
The association between reduced bile acid synthesis and reduced serum levels of triglyceride and 
apolipoprotein B100 [114] once again supports the hypothesis of coordinate regulation between bile 
acid and triglyceride/lipoprotein [116]. 
Statins, competitive inhibitors of HMG-CoA reductase, represent the mainstay of cholesterol-lowering 
treatment. The transient inhibition of cholesterol synthesis induced by statins triggers SREBP-mediated 
transcription of enzymes of the cholesterol biosynthetic pathway and of the LDL receptor [158], 
lowering LDL-cholesterol levels. Statins are a model to study the regulatory role of newly synthesized 
cholesterol on bile acid metabolism. Distinctly different effects were shown in relation to the different 
experimental models and settings. Indeed, most evidence currently available in humans in vivo and  
in vitro seems to exclude a significant effect of chronic statin treatment on bile acid synthesis and 
CYP7A1 activity [4,101,102,158,159].  
Apparently, under stabilized conditions the homeostatic responses triggered by inhibition of 
cholesterol synthesis can restore an adequate supply of cholesterol for bile acid synthesis. On the other 
hand, when statin treatment was superimposed to a chronic stimulation of bile acid synthesis with resin 
treatment, a reduction in cholesterol 7α-hydroxylation rates in vivo was disclosed, as measured by 
isotope release [156]. Similar data were also obtained in bile fistula patients [160].  
Changes in synthetic rates in vivo paralleled changes in plasma lathosterol to cholesterol ratio [156], 
suggesting that the availability of newly synthesized cholesterol may be critical for bile acid formation 
in stimulated conditions. An involvement of hepatic nuclear receptors seems likely, even if no direct 
evidence is available in humans. 
Preliminary evidence is also available on the effects of statin treatment on the production of  
27-hydroxycholesterol, measured in vivo by steady-state stable isotope infusion [116]. Treatment with 
two different statins, atorvastatin and rosuvastatin, was shown to reduce significantly 27-hydroxylation 
rates in parallel with a drastic reduction of serum cholesterol. As commented before, the  
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changes observed seem to support the view that plasma cholesterol is the main determinant of  
27-hydroxycholesterol formation, even if direct drug effects cannot be completely ruled out. 
6.7.2. Other Drugs 
Apart from drugs affecting lipid metabolism, a few pieces of evidence are available on the effects 
induced on bile acid synthesis by different pharmacological treatments.  
Because of the high risk of developing gallstones in women using oral steroid contraceptives, the 
effects of such drugs was investigated in bile acid kinetic studies [161–163]. Production rate and pool 
size of CA were increased but bile acid secretion was decreased, probably due to decreased recycling. 
Synthesis rates and pool size of CDCA on the contrary tended to be reduced. However cholesterol 
secretion significantly increased, accounting for the observed increase in biliary saturation. A 
significant increase in biliary cholesterol saturation was also observed after administration of 
conjugated estrogens (Premarin), which associated with reduced synthesis of CDCA [164]. 
Corticosteroid treatment is extensively utilized in clinical medicine, with a wide array of indications 
which embrace gastrointestinal diseases as well. Short term treatment with methyl-prednisolone in 
patients with primary biliary cirrhosis was shown to increase fractional turnover and synthesis rates of 
CA, assayed by stable isotope dilution technique [165]. Steroid treatment also increased the biliary 
output of DCA. These findings, although encouraging in terms of changes in biliary cholesterol 
saturation, warrant caution with respect to the possible hepatotoxic effects of DCA accumulation. 
Treatment with the somatostatin analogue octreotide was also studied with stable isotope 
administration technique; in patients with acromegaly, a typical indication for octreotide treatment, 
such treatment did not induce any changes in CA synthesis rate, but increased significantly the output 
of the secondary bile acid DCA [166]. The finding was related to prolongation of large bowel transit, 
and may play a role as a causal or contributor factor in the pathogenesis of octreotide-related 
appearance of gallstone disease. Growth hormone treatment, on the other hand, was not found to alter 
biliary lipid metabolism and bile acid synthesis in healthy adult men [167]. 
7. Concluding Remarks 
During the last decade, an extraordinary body of evidence has clarified many aspects of cholesterol 
catabolism to bile acids: deep insight in the molecular mechanisms of regulation of bile acid synthesis 
has been reached, and the transcriptional control of CYP7A1 has been defined in great detail along 
with the regulatory role of nuclear receptors and transcriptional coactivators. Likewise, the role of the 
alternate pathway of bile acid synthesis and the regulation of CYP27 have been underlined and defined 
as well. Such progress was made possible, among others, by the widespread implementation of 
molecular biology techniques. 
Nonetheless in vivo tracer kinetics studies in the field of cholesterol metabolism and degradation, in 
humans as well as in animal models, still maintain an exceptional scientific and speculative relevance. 
On one hand, they allow to overcome the ethical and technical problems concerning invasive 
procedures, such as liver biopsy, which are needed to perform tissue analysis of enzyme expression 
and activity. Furthermore, most of the in vivo procedures which have been validated so far allow 
quantitative determination of cholesterol degradation in the unit of time; this represents an obvious 
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advantage towards the assays in vitro, and also towards the determination of circulating levels of 
metabolic precursors, which can certainly be considered a reliable and convenient tool for studies in 
larger populations, but can provide only comparative, or at the most semi-quantitative, data. The 
information obtained in tracer studies can be utilized for balance studies, or simulations, regarding 
cholesterol homeostasis. 
It must also be recalled that evidence obtained from tissue analysis in vitro does not always reflect 
the findings obtained in in vivo studies: this usually represents a challenging situation, and sometimes 
allows interesting pathophysiological speculations (e.g., the presence of post-transcriptional levels of 
control, competitive inhibition that cannot be detected by in vitro assays, and so on). Tracer studies  
in vivo, therefore, can be considered a valuable complement, rather than an alternative, to the analyses 
on tissues in vitro.  
Nowadays studies with non-radioactive stable isotopes have virtually replaced the older approaches 
with radiolabels, and have become the gold standard for kinetic studies in vivo due to the absence of 
radiological invasiveness. Once again, widespread use of GS-MS expertise will likely make those 
approaches more largely available to the scientific community. 
Tracer kinetic studies can prove as exceptional tools for the investigation of sterol metabolism in 
the future, as they have been in the past; their speculative and translational implications will hopefully 
help to disclose new pathophysiological knowledge, and maybe novel management strategies, in the 
field of cholesterol accumulation conditions and their important clinical consequences. 
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